Ibere Pharmaceuticals registered today with the SEC to offer 10 million units priced at $10 each.
The new SPAC is targeting a large addressable market as total worldwide prescription drug sales lost due to patent expiration from 2020 through 2026 is expected to be approximately $252 billion, according to EvaluatePharma.
The SPAC is led by Chairman and CEO Osagie Imasogie who currently serves as a co-founder and senior managing partner of Philadelphia-based PIPV Capital.
Ibere plans to list on the NYSE under IBERU. Read more.
